Alliance for Clinical Trials in Oncology/X
Aug 6, 2025, 08:08
Is Less Treatment Needed After Surgery for Early-Stage HER2+ Breast Cancer – Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology shared a post on X:
“New Trial!
Ada Waks of Dana-Farber Cancer Institute leads Alliance for Clinical Trials in Oncology A012303 (ShortStop-HER2), a study exploring if less treatment is needed after surgery for people with early-stage HER2+ breast cancer who had no cancer left after chemo + HER2 therapy (before surgery).”
Sarah Sammons, Associate Director of the Metastatic Breast Cancer Program at Dana-Farber Cancer Institute, shared Alliance for Clinical Trials in Oncology‘s post, adding:
“This is where the importance of government cancer funding comes in.
My brilliant colleague designing a large trial to give less trastuzumab to HER2+ patients who achieve pCR.”
More posts featuring Breast Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 6, 2025, 08:05
Aug 6, 2025, 07:04
Aug 6, 2025, 06:42
Aug 6, 2025, 06:26
Aug 6, 2025, 05:59